|
Total, n (%)
|
107
|
37 (35)
| |
|
Age at primary diagnosis, years; median (range)
|
49 (33–81)
|
49 (35–77)
|
0.594
|
|
Age at enrollment, years; median (range)
|
57 (33–81)
|
58 (40–77)
|
0.517
|
|
ER status, n (%)
| | |
0.253
|
|
Negative
|
78
|
30 (38)
| |
|
Positive
|
29
|
7 (24)
| |
|
PR status, n (%)
| | |
0.673
|
|
Negative
|
68
|
25 (37)
| |
|
Positive
|
39
|
12 (31)
| |
|
Number of metastatic sites, n (%)
| | |
0.799
|
|
One site
|
21
|
8 (38)
| |
|
Multiple sites
|
86
|
29 (34)
| |
|
Site of metastasis, n (%)
| | |
0.626
|
|
Bone
|
19
|
5 (26)
| |
|
Visceral
|
22
|
7 (32)
| |
|
Both
|
66
|
25 (38)
| |
|
Line of therapy, n (%)a
| | |
0.268
|
|
First
|
51
|
18 (35)
| |
|
Second
|
22
|
10 (45)
| |
|
Further
|
33
|
8 (24)
| |
